Considering the limited number of studies that investigated these genes, we conducted this prospective study to determine whether the GSTM1, GSTT1, and GSTP1 Ile105Val polymorphisms alter toxicity, response rate, and survival in HNSCC patients treated with CDDP and RT. This evidence concerns the gene GSTP1 and head and neck squamous cell carcinoma.